A Kenyan doctor, who wrote a book on the first genetic vaccine for AIDS to go to court, said that one day the virus is under controlled

Dr. Matilu Mwau international news 10 years ago as a graduate student in the UK in search work group to study the vaccine in humans has been created.

He said, he suffered a combination of factors, including treatment, prevention and the use of an effective vaccine is years too late to tame virus misery for the human race.

Because of the great interest that scientists have the virus, and have accumulated vast amounts of knowledge over the years, the world is moving forward with better products and more powerful anti-retroviral Mwau said.

Dr. Mwatilu Mwau says the future looks bright for the eradication of the AIDS pandemic. [Image: Jenipher Wachi]

And this is a matter of time before an effective vaccine is found, he added. However, he argues that a vaccine similar to that used for measles, typhus, smallpox or polio, which works by stimulating the immune system, probably not a panacea for HIV. Instead, it is an effective vaccine against HIV must not only stimulate the production of neutralizing antibodies, but also the specific cell-mediated response as well.

In 2007, the failure of a vaccine in clinical trials submitted by pharmaceutical giant Merck, a wave of pessimism crashing to the researchers. As at the time the leading candidate for an effective AIDS vaccine that has failed - and some evidence that this may have increased the risk of HIV infection - the researchers to dig his head. Three years later, in September last year there was a glimmer of hope if U.S. and Thai researchers, the test results revealed the largest ever vaccine. Testing more than 16,000 images of Thais offered ALVAC and AIDSVAX vaccine protection against 31.2 percent the risk of infection.

Mwau his feelings before World AIDS Day, Wednesday, marks, and the weekend that some researchers have discovered a pill every day that capture the risk of infection, reductions of up to 90 percent.

HIV / AIDS experts and interest groups welcomed the results of a three-year study in the New England Journal of Medicine was published as a turning point in the global fight against the deadly virus. It combines two antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate in one tablet, and has been used to treat HIV since 2002.

Among men who received placebo, 64 HIV was responsible for the three years of study. The group was 36 HIV infections, but two of those before the study and 31 of the 34 men, others had not used drugs in the blood, have not taken the pills. Researchers in that a rate of 90 percent of success in the field of HIV. In the United States sold the drug, Truvada, for about $ 1,000 (SH80, 000) per month.

During his studies at the University of Oxford in the UK, wrote a thesis entitled Mwau: Clinical evaluation of a candidate HIV-1 subtype A / DNA-MVA vaccine specific for Kenya.

He studied the safety and immunogenicity of the vaccine by genetic scientists at the University of Oxford. There are about 86 products in clinical trials of vaccines. However the world is still waiting for a vaccine against the disease that has infected so far killed 25 million and 33 million people around the world, even if life ARV should be extended.
Mwau, Centre for Infectious and Parasitic Diseases Control and Research, Kenya Medical Research Institute of Busia leaders said the future looks promising for the eradication of the pandemic. Avoid the common efforts of people in the world of contracting the virus is a major cause that will be given.

"The efforts to be faithful to a HIV-negative partners, condom use, abstinence, circumcision and early childhood assessment and treatment have all worked very hard in Kenya, he said. He also said that it would be one way the virus has weakened over the years. "If the flu virus has killed millions of pandemic occurred in 1918. Today, a simple flu virus, which can be treated at home because," he said.